Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies - PubMed (original) (raw)

Review

. 2012 Feb 14;9(3):167-77.

doi: 10.1038/nrclinonc.2012.2.

Affiliations

• PMID: 22330689
• DOI: 10.1038/nrclinonc.2012.2

Review

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

James P B O'Connor et al. Nat Rev Clin Oncol. 2012.

Abstract

About 100 early-phase clinical trials and investigator-led studies of targeted antivascular therapies--both anti-angiogenic and vascular-targeting agents--have reported data derived from T1-weighted dynamic contrast-enhanced (DCE)-MRI. However, the role of DCE-MRI for decision making during the drug-development process remains controversial. Despite well-documented guidelines on image acquisition and analysis, several key questions concerning the role of this technique in early-phase trial design remain unanswered. This Review describes studies of single-agent antivascular therapies, in which DCE-MRI parameters are incorporated as pharmacodynamic biomarkers. We discuss whether these parameters, such as volume transfer constant (K(trans)), are reproducible and reliable biomarkers of both drug efficacy and proof of concept, and whether they assist in dose selection and drug scheduling for subsequent phase II trials. Emerging evidence indicates that multiparametric analysis of DCE-MRI data offers greater insight into the mechanism of drug action than studies measuring a single parameter, such as K(trans). We also provide an overview of current data and appraise the future directions of this technique in oncology trials. Finally, major hurdles in imaging biomarker development, validation and qualification that hinder a wide application of DCE-MRI techniques in clinical trials are addressed.

PubMed Disclaimer

Similar articles

• DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.
  Chen BB, Shih TT. Chen BB, et al. World J Gastroenterol. 2014 Mar 28;20(12):3125-34. doi: 10.3748/wjg.v20.i12.3125. World J Gastroenterol. 2014. PMID: 24695624 Free PMC article. Review.
• Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.
  Padhani AR, Leach MO. Padhani AR, et al. Abdom Imaging. 2005 May-Jun;30(3):324-41. doi: 10.1007/s00261-004-0265-5. Abdom Imaging. 2005. PMID: 15688112 Review.
• DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.
  O'Connor JP, Jackson A, Parker GJ, Jayson GC. O'Connor JP, et al. Br J Cancer. 2007 Jan 29;96(2):189-95. doi: 10.1038/sj.bjc.6603515. Epub 2007 Jan 9. Br J Cancer. 2007. PMID: 17211479 Free PMC article. Review.
• Dynamic contrast-enhanced MRI for oncology drug development.
  Sung YS, Park B, Choi Y, Lim HS, Woo DC, Kim KW, Kim JK. Sung YS, et al. J Magn Reson Imaging. 2016 Aug;44(2):251-64. doi: 10.1002/jmri.25173. Epub 2016 Feb 8. J Magn Reson Imaging. 2016. PMID: 26854494 Review.
• MRI for assessing antivascular cancer treatments.
  Padhani AR. Padhani AR. Br J Radiol. 2003;76 Spec No 1:S60-80. doi: 10.1259/bjr/15334380. Br J Radiol. 2003. PMID: 15456715 Review.

Cited by

• MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
  Cebulla J, Huuse EM, Pettersen K, van der Veen A, Kim E, Andersen S, Prestvik WS, Bofin AM, Pathak AP, Bjørkøy G, Bathen TF, Moestue SA. Cebulla J, et al. Br J Cancer. 2015 Feb 3;112(3):504-13. doi: 10.1038/bjc.2014.628. Epub 2014 Dec 23. Br J Cancer. 2015. PMID: 25535727 Free PMC article.
• Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
  Das S, Dey MK, Devireddy R, Gartia MR. Das S, et al. Sensors (Basel). 2023 Dec 20;24(1):37. doi: 10.3390/s24010037. Sensors (Basel). 2023. PMID: 38202898 Free PMC article. Review.
• Identification of Predominant Histopathological Growth Patterns of Colorectal Liver Metastasis by Multi-Habitat and Multi-Sequence Based Radiomics Analysis.
  Han Y, Chai F, Wei J, Yue Y, Cheng J, Gu D, Zhang Y, Tong T, Sheng W, Hong N, Ye Y, Wang Y, Tian J. Han Y, et al. Front Oncol. 2020 Aug 14;10:1363. doi: 10.3389/fonc.2020.01363. eCollection 2020. Front Oncol. 2020. PMID: 32923388 Free PMC article.
• Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma.
  Lewis D, Roncaroli F, Agushi E, Mosses D, Williams R, Li KL, Zhu X, Hinz R, Atkinson R, Wadeson A, Hulme S, Mayers H, Stapleton E, Lloyd SKL, Freeman SR, Rutherford SA, Hammerbeck-Ward C, Evans DG, Pathmanaban O, Jackson A, King AT, Coope DJ. Lewis D, et al. Neuro Oncol. 2019 Feb 19;21(3):314-325. doi: 10.1093/neuonc/noy177. Neuro Oncol. 2019. PMID: 30388263 Free PMC article.
• Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer.
  Lee SH, Rimner A, Gelb E, Deasy JO, Hunt MA, Humm JL, Tyagi N. Lee SH, et al. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):718-726. doi: 10.1016/j.ijrobp.2018.02.031. Epub 2018 Mar 2. Int J Radiat Oncol Biol Phys. 2018. PMID: 29680254 Free PMC article.

References

1. 1. Clin Cancer Res. 2011 Aug 1;17(15):5152-60 - PubMed
2. 1. J Clin Oncol. 2008 Jun 20;26(18):2992-8 - PubMed
3. 1. J Clin Oncol. 2009 Sep 1;27(25):4169-76 - PubMed
4. 1. J Angiogenes Res. 2009 Sep 21;1:5 - PubMed
5. 1. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information